A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

A PHASE 2B, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF MULTIPLE DOSE LEVELS OF PF-07038124 OINTMENT FOR 12 WEEKS IN PARTICIPANTS 12 YEARS AND OLDER AND WITH MILD-TO-MODERATE ATOPIC DERMATITIS OR MILD-TO-SEVERE PLAQUE PSORIASIS

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05375955

Enrollment

263

Registered

2022-05-17

Start date

2022-09-26

Completion date

2023-07-31

Last updated

2024-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis, Plaque Psoriasis

Keywords

Eczema, topical

Brief summary

The purpose of this clinical trial is to learn about the safety, how well the study medicine works, extent to which side effects can be tolerated, and how the study medicine is changed and eliminated from your body after you apply it on your skin. The study medicine is in ointment form. This study is seeking participants who If they have Atopic Dermatitis (AD): * Have a diagnosis for at least 3 months * Have a diagnosis of mild or moderate disease assessed using Investigator's Global Assessment (IGA) * Have percent Body Surface Area (%BSA) covering 5% up to 40% * A Peak Pruritus Numerical Rating Scale (PP-NRS) average score of ≥2 during the screening period If they have plaque psoriasis (PsO): * Have a diagnosis for at least 6 months * Have a diagnosis of mild, moderate, or severe disease assessed using Physician's Global Assessment (PGA) * Have percent Body Surface Area (%BSA) covering 2% up to 20% All participants in this study will receive either 0.01% PF-07038124, 0.03% PF-07038124, or a vehicle ointment. In addition, some participants with PsO will receive 0.06% PF- PF-07038124. Participants will not know which dose level they have received. The participants will be randomly assigned to each dose group. PF-07038124 ointment will be applied topically to affected areas once daily. We will compare the experiences of people receiving the different dose levels of the ointment to those who receive the vehicle ointment. This will help us determine if PF-07038124 ointment is safe and effective. Participants will take part in this study for approximately 21 weeks. Participants will apply the study medicine once daily for 12 weeks followed by a safety follow-up period of 4-5 weeks from last application of study medicine to last visit.

Interventions

DRUGPF-07038124 ointment 0.01%

Atopic Dermatitis and Plaque Psoriasis

DRUGVehicle ointment

Atopic Dermatitis and Plaque Psoriasis

DRUGPF-07038124 ointment 0.03%

Atopic Dermatitis and Plaque Psoriasis

DRUGPF-07038124 ointment 0.06%

PF-07038124 ointment 0.06% (Plaque Psoriasis only)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

for AD population: * Diagnosis of Atopic Dermatitis (AD) for at least 3 months * Investigator's Global Assessment (IGA) score of 2 (mild), or 3 (moderate) * AD covering 5% and up to 40% of Body Surface Area (BSA) * A Peak Pruritus Numerical Rating Scale (PP-NRS) average score of ≥2 Inclusion Criteria for Plaque Psoriasis * Diagnosis of Plaque Psoriasis (PsO) for at least 6 months * Physician Global Assessment (PGA) score of 2 (mild), 3 (moderate), or 4 (severe) * PsO covering 2% to 20% (inclusive) of BSA

Exclusion criteria

* Presence of skin comorbidities that would interfere with study assessment or response to treatment * Psychiatric condition including recent or active suicidal ideation or behavior * Current or recent history of severe, progressive, or uncontrolled disease * A history of systemic, chronic or acute skin infection requiring hospitalization, parenteral antimicrobial therapy, or is judged clinically significant. * Recent, significant trauma or major surgery * History of cancer or have undergone treatment for any type of cancer, with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ with no evidence of recurrence. * History of angioedema or anaphylaxis to topical products or known sensitivity to any of the components of the investigational products. * Use of any prohibited concomitant medication(s) * Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). * Participants with an estimated glomerular filtration rate (eGFR) of \<40 mL/min/1.73m2 calculated using the serum creatinine-based Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula for adults and serum creatinine \>1.5 x upper limit of normal (ULN) in adolescents (12-18 years old) * Participants with total bilirubin ≥2x ULN (≥3 x ULN for Gilbert's disease), aspartate aminotransferase (AST) ≥2.5 x ULN, ALT ≥2.5 x ULN. * Clinically relevant abnormal baseline standard 12-lead electrocardiogram (ECG) including, but not limited to QTC corrected using Fridericia's Formula (QTcF) interval \>450 msec and QRS \> 120 msec * A recent history of alcohol or substance abuse

Design outcomes

Primary

Measure	Time frame	Description
Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=) 2 Points at Week 12: Participants With Atopic Dermatitis (AD) Only	Baseline, Week 12	IGA assessed severity of AD on 5-point scale ranging from 0(clear)to 4(severe)higher scores indicate more severity,reflecting a global consideration of erythema (ery),induration and scaling. Clinical evaluator assessed overall severity of AD and assigned IGA score as follows: 0 (clear) no inflammatory signs of AD; 1=almost clear, AD not fully cleared-light pink residual lesions(except post-inflammatory hyperpigmentation),just perceptible ery, papulation/induration lichenification, excoriation, no oozing/crusting; 2=mild AD with light red lesions, slight but definite ery, papulation/induration, lichenification, excoriation, no oozing/crusting; 3=moderate AD with red lesions, moderate ery, papulation/induration, lichenification, excoriation, slight oozing/crusting; 4=severe AD with deep dark red lesions, severe ery, papulation/induration, lichenification, excoriation, moderate to severe oozing/crusting.95 percentage (%)confidence interval was based on Blyth-Still-Casella method.
Percentage of Participants With Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Week 12: Participants With Plaque Psoriasis Only	Baseline, Week 12	The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). In this OM, percentages of participants with a PGA score of 0 or 1 and an improvement of \>=2 from Baseline in PGA score were reported. 95% confidence interval (CI) was based on Blyth-Still-Casella method.

Secondary

Measure	Time frame	Description
Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Baseline, Week 1, 2, 4, 6, 8, and 10	IGA assessed severity of AD on 5-point scale ranging from 0(clear)to 4(severe)higher scores indicate more severity,reflecting a global consideration of erythema (ery),induration and scaling. Clinical evaluator assessed overall severity of AD and assigned IGA score as follows: 0 (clear) no inflammatory signs of AD; 1=almost clear, AD not fully cleared-light pink residual lesions(except post-inflammatory hyperpigmentation),just perceptible ery, papulation/induration lichenification, excoriation, no oozing/crusting; 2=mild AD with light red lesions, slight but definite ery, papulation/induration, lichenification, excoriation, no oozing/crusting; 3=moderate AD with red lesions, moderate ery, papulation/induration, lichenification, excoriation, slight oozing/crusting; 4=severe AD with deep dark red lesions, severe ery, papulation/induration, lichenification, excoriation, moderate to severe oozing/crusting.95%confidence interval was based on Blyth-Still-Casella method.
Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Baseline, Week 1, 2, 4, 6, 8, and 10	The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). In this OM, percentages of participants with a PGA score of 0 or 1 and an improvement of \>=2 from Baseline in PGA score were reported. 95% confidence interval was based on Blyth-Still-Casella method.
Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 1, 2, 4, 6, 8, 10 and 12	IGA assessed severity of AD on 5-point scale ranging from 0(clear)to 4(severe)higher scores indicate more severity,reflecting a global consideration of erythema (ery),induration and scaling. Clinical evaluator assessed overall severity of AD and assigned IGA score as follows: 0 (clear) no inflammatory signs of AD; 1=almost clear, AD not fully cleared-light pink residual lesions(except post-inflammatory hyperpigmentation),just perceptible ery, papulation/induration lichenification, excoriation, no oozing/crusting; 2=mild AD with light red lesions, slight but definite ery, papulation/induration, lichenification, excoriation, no oozing/crusting; 3=moderate AD with red lesions, moderate ery, papulation/induration, lichenification, excoriation, slight oozing/crusting; 4=severe AD with deep dark red lesions, severe ery, papulation/induration, lichenification, excoriation, moderate to severe oozing/crusting. 95% confidence interval was based on Blyth-Still-Casella method.
Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1, 2, 4, 6, 8, 10 and 12	The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). 95% confidence interval was based on Blyth-Still-Casella method.
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Baseline, Week 1, 2, 4, 6, 8, 10 and 12	EASI quantified severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation \[I\], excoriation \[Ex\] and lichenification \[L\]) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\Ah\(Eh+Ih+Exh+Lh) + 0.2\Au\(Eu+Iu+ExU+Lu) + 0.3\At\(Et+It+Ext+Lt) + 0.4\Al\(El+Il+Exl+Ll); A = EASI area score; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score=0.0 to 72.0, higher scores indicate greater severity of AD. 95% confidence interval was based on Blyth-Still-Casella method.
Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Baseline, Week 1, 2, 4, 6, 8, 10 and 12	The PASI quantified the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI was a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score could vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI =0.1Ah(Eh+Ih+Sh) + 0.2Au(Eu+Iu+Su) + 0.3At(Et+It+St) + 0.4Al(El+Il+Sl) (A= PASI area score,S=scaling)PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. 95% confidence interval was based on Blyth-Still-Casella method.
Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Baseline, Week 1, 2, 4, 6, 8, 10 and 12	The PP-NRS was a daily participant reported assessment of intensity of pruritus on an 11-point numerical rating scale ranging from 0 ('No Itch) to 10 ('Worst Itch Imaginable'), with a 24-hour recall period. Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. For the PP-NRS score, baseline was defined as the average of all values recorded between Day -7 (7 days prior to dosing) and Day -1 (1 day prior to dosing). In this OM, percentages of AD participants with \>=4 points of reduction in weekly averages of PP-NRS from baseline are reported (percentage based on number of participants with baseline \>=4).
Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Baseline, Week 1, 2, 4, 6, 8, 10 and 12	EASI quantified severity of AD based on severity of lesion clinical signs and % of body surface area(BSA)affected.Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation\[I\],excoriation\[Ex\] and lichenification\[L\]) were scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin)\], lower limbs \[including buttocks\]) on a 4-point scale:0= absent; 1= mild;2= moderate;3= severe.EASI area score was based on % BSA with AD in body region: 0(0%), 1(\>0 to \<10%),2 (10 to \<30%), 3(30 to \<50%), 4(50 to \<70%), 5(70 to \<90%) and 6(90 to 100%).Total EASI score =0.1\Ah\(Eh+Ih+Exh+Lh) + 0.2\Au\(Eu+Iu+ExU+Lu)+0.3\At\(Et+It+Ext+Lt)+0.4\Al\(El+Il+Exl+Ll);A= EASI area score;h= head and neck;u= upper limbs;t= trunk;l= lower limbs.Total EASI score=0.0 to 72.0, higher scores indicate greater severity of AD.EASI 75 response was defined as at least a 75% reduction in EASI relative to Baseline.95% CI was based on Blyth-Still-Casella method.
Percent Change From Baseline in Affected Body Surface Area (BSA) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis and Plaque Psoriasis	Baseline, Week 1, 2, 4, 6, 8, 10 and 12	Four body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin) and lower limbs (including buttocks). Scalp, palms and soles were excluded. BSA was calculated using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Maximum number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall percentage (%) BSA for individuals with AD ranged from 5-40 % BSA and for individuals with Psoriasis ranged from 2-20 % BSA. Higher % BSA = greater area affected.
Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis	From start of study treatment up to 35 days after last dose of treatment (up to 19 weeks)	An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered TEAE if the event occurred on or after the first dosing date but before the last dose plus the lag time (35 days).
Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis	From start of study treatment up to 35 days after last dose of treatment (up to 19 weeks)	An SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other important medical events.
Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis	From start of study treatment (Day 1) up to Week 12	Temperature, pulse rate, and blood pressure were assessed in vital sign examination. Body temperature was collected using oral, tympanic, axillary or temporal methods. Blood pressure and pulse rate measurements were assessed with the participant in a supine or seated position using a completely automated device after at least 5 minutes of rest for the participant. Clinically significant changes were determined by the investigator.
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis	From start of study treatment (Day 1) up to Week 12	A standard 12-lead ECG utilizing limb leads was collected using ECG machine that automatically calculated the heart rate and measured pulse rate, QT, and QTc intervals and QRS complex. Clinically significant findings (including, but not limited to, changes from baseline in QTcF after enrollment) were determined by the investigator or qualified designee.
Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis	From start of study treatment (Day 1) up to Week 12	Laboratory assessments included hematology, clinical chemistry and urinalysis. Clinically significant abnormal laboratory findings were those which were not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.
Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	From start of study treatment (Day 1) up to Week 12	The investigator or designee assessed tolerability at the site of study intervention application, immediately post-application of the study intervention. Skin Tolerability Grading System for non-lesional skin included grade 0 (No evidence of local intolerance), grade 1 (Mild-Minimal erythema and/or edema, slight glazed appearance), grade 2 (Moderate-Definite erythema and/or edema with peeling and/or cracking but needs no adaptation of posology), grade 3 (Severe-Erythema, edema glazing with fissures, few vesicles or papules: consider removing topical agent \[if still in place\], grade 4 (very severe- Strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\].
Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1, 2, 4, 6, 8, 10 and 12	The PP-NRS was a daily participant reported assessment of intensity of pruritus on an 11-point numerical rating scale ranging from 0 ('No Itch) to 10 ('Worst Itch Imaginable'), with a 24-hour recall period. Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. For the PP-NRS score, baseline was defined as the average of all values recorded between Day -7 (7 days prior to dosing) and Day -1 (1 day prior to dosing). In this OM, percentages of plaque psoriasis participants (18-75 years old) with \>=4 points of reduction in weekly averages of PP-NRS from baseline are reported (percentage based on number of participants with baseline \>=4).
Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Baseline, Week 1, 2, 4, 6, 8, 10 and 12	The PASI quantified the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI was a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score could vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI score =0.1Ah(Eh+Ih+Sh) + 0.2Au(Eu+Iu+Su) + 0.3At(Et+It+St) + 0.4Al(El+Il+Sl) (A= PASI area score,S=scaling)PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. 95% confidence interval was based on Blyth-Still-Casella method.

Countries

Canada, Japan, United Kingdom, United States

Participant flow

Pre-assignment details

A total of 263 participants were enrolled and randomized in the study.

Participants by arm

Arm	Count
Atopic Dermatitis: Vehicle Ointment Participants with mild or moderate atopic dermatitis applied the vehicle ointment topically on affected areas once daily (QD) for 12 weeks.	44
Atopic Dermatitis: PF-07038124 0.01% Ointment Participants with mild or moderate atopic dermatitis applied PF-07038124 0.01% ointment topically on affected areas QD for 12 weeks.	42
Atopic Dermatitis: PF-07038124 0.03% Ointment Participants with mild or moderate atopic dermatitis applied PF-07038124 0.03% ointment topically on affected areas QD for 12 weeks.	42
Psoriasis: PF-07038124 Vehicle Ointment Participants with mild, moderate, or severe psoriasis applied PF-07038124 0% ointment topically on affected areas QD for 12 weeks.	34
Psoriasis: PF-07038124 0.01% Ointment Participants with mild, moderate, or severe psoriasis applied PF-07038124 0.01% ointment topically on affected areas QD for 12 weeks.	33
Psoriasis: PF-07038124 0.03% Ointment Participants with mild, moderate, or severe psoriasis applied PF-07038124 0.03% ointment topically on affected areas QD for 12 weeks.	35
Psoriasis: PF-07038124 0.06% Ointment Participants with mild, moderate, or severe psoriasis applied PF-07038124 0.06% ointment topically on affected areas QD for 12 weeks.	33
Total	263

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003	FG004	FG005	FG006
Follow-up (up to 5 Weeks)	Lost to Follow-up	1	0	1	0	1	1	2
Follow-up (up to 5 Weeks)	Other	0	1	0	0	0	0	0
Follow-up (up to 5 Weeks)	Physician's decision	2	0	2	0	0	0	0
Follow-up (up to 5 Weeks)	Protocol Violation	0	0	1	0	0	0	0
Follow-up (up to 5 Weeks)	Withdrawal by Subject	1	0	1	0	0	1	0
Treatment (12 Weeks)	Lost to Follow-up	0	2	2	1	1	1	0
Treatment (12 Weeks)	Other	0	1	0	0	0	0	0
Treatment (12 Weeks)	Physician Decision	4	1	3	0	0	1	0
Treatment (12 Weeks)	Pregnancy	0	0	1	0	0	0	0
Treatment (12 Weeks)	Withdrawal by parent/guardian	0	0	0	0	0	0	1
Treatment (12 Weeks)	Withdrawal by Subject	8	4	7	8	4	3	3

Baseline characteristics

Characteristic	Atopic Dermatitis: Vehicle Ointment	Atopic Dermatitis: PF-07038124 0.01% Ointment	Atopic Dermatitis: PF-07038124 0.03% Ointment	Psoriasis: PF-07038124 Vehicle Ointment	Psoriasis: PF-07038124 0.01% Ointment	Psoriasis: PF-07038124 0.03% Ointment	Psoriasis: PF-07038124 0.06% Ointment	Total
Age, Continuous	44.8 Years STANDARD_DEVIATION 18.55	44.1 Years STANDARD_DEVIATION 15.31	40.0 Years STANDARD_DEVIATION 16.28	52.6 Years STANDARD_DEVIATION 12.28	47.8 Years STANDARD_DEVIATION 13.37	55.7 Years STANDARD_DEVIATION 15.11	50.0 Years STANDARD_DEVIATION 17.33	51.6 Years STANDARD_DEVIATION 14.77
Ethnicity (NIH/OMB) Hispanic or Latino	7 Participants	11 Participants	8 Participants	16 Participants	11 Participants	7 Participants	6 Participants	66 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	35 Participants	29 Participants	32 Participants	17 Participants	22 Participants	25 Participants	27 Participants	187 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	2 Participants	2 Participants	2 Participants	1 Participants	0 Participants	3 Participants	0 Participants	10 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Asian	8 Participants	8 Participants	13 Participants	7 Participants	4 Participants	8 Participants	12 Participants	60 Participants
Race (NIH/OMB) Black or African American	13 Participants	11 Participants	12 Participants	0 Participants	1 Participants	2 Participants	0 Participants	39 Participants
Race (NIH/OMB) More than one race	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants	0 Participants	1 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants	2 Participants	0 Participants	1 Participants	1 Participants	0 Participants	1 Participants	5 Participants
Race (NIH/OMB) White	23 Participants	20 Participants	17 Participants	25 Participants	27 Participants	25 Participants	20 Participants	157 Participants
Sex: Female, Male Female	23 Participants	25 Participants	23 Participants	14 Participants	13 Participants	14 Participants	15 Participants	127 Participants
Sex: Female, Male Male	21 Participants	17 Participants	19 Participants	20 Participants	20 Participants	21 Participants	18 Participants	136 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk
deaths Total, all-cause mortality	0 / 44	0 / 42	0 / 42	0 / 34	0 / 33	0 / 35	0 / 33
other Total, other adverse events	0 / 44	5 / 42	2 / 42	1 / 34	5 / 33	2 / 35	7 / 33
serious Total, serious adverse events	0 / 44	1 / 42	1 / 42	0 / 34	0 / 33	0 / 35	1 / 33

Outcome results

Primary

Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=) 2 Points at Week 12: Participants With Atopic Dermatitis (AD) Only

IGA assessed severity of AD on 5-point scale ranging from 0(clear)to 4(severe)higher scores indicate more severity,reflecting a global consideration of erythema (ery),induration and scaling. Clinical evaluator assessed overall severity of AD and assigned IGA score as follows: 0 (clear) no inflammatory signs of AD; 1=almost clear, AD not fully cleared-light pink residual lesions(except post-inflammatory hyperpigmentation),just perceptible ery, papulation/induration lichenification, excoriation, no oozing/crusting; 2=mild AD with light red lesions, slight but definite ery, papulation/induration, lichenification, excoriation, no oozing/crusting; 3=moderate AD with red lesions, moderate ery, papulation/induration, lichenification, excoriation, slight oozing/crusting; 4=severe AD with deep dark red lesions, severe ery, papulation/induration, lichenification, excoriation, moderate to severe oozing/crusting.95 percentage (%)confidence interval was based on Blyth-Still-Casella method.

Time frame: Baseline, Week 12

Population: Intent-to-treat (ITT) analysis set included all participants randomly assigned to study intervention. For this outcome measure (OM), data collection was not planned for the 4 arms of Psoriasis Vehicle QD, Psoriasis PF-07038124 0.01% QD, Psoriasis PF-07038124 0.03% and Psoriasis PF-07038124 0.06% ointment.

Arm	Measure	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=) 2 Points at Week 12: Participants With Atopic Dermatitis (AD) Only	11.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=) 2 Points at Week 12: Participants With Atopic Dermatitis (AD) Only	23.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With Investigator's Global Assessment (IGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of More Than or Equal to (>=) 2 Points at Week 12: Participants With Atopic Dermatitis (AD) Only	21.4 Percentage of participants

p-value: 0.071195% CI: [-4.1, 29.4]Chan and Zhang (1999) method

p-value: 0.12995% CI: [-6.1, 26.8]Chan and Zhang (1999) method

Primary

Percentage of Participants With Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Week 12: Participants With Plaque Psoriasis Only

The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). In this OM, percentages of participants with a PGA score of 0 or 1 and an improvement of \>=2 from Baseline in PGA score were reported. 95% confidence interval (CI) was based on Blyth-Still-Casella method.

Time frame: Baseline, Week 12

Population: ITT analysis set included all participants randomly assigned to study intervention. For this OM, data collection was not planned for the 3 arms of AD Vehicle QD, AD PF-07038124 0.01% QD and AD PF-07038124 0.03% QD.

Arm	Measure	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Week 12: Participants With Plaque Psoriasis Only	8.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Week 12: Participants With Plaque Psoriasis Only	15.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Week 12: Participants With Plaque Psoriasis Only	37.1 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With Physician's Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Week 12: Participants With Plaque Psoriasis Only	45.5 Percentage of participants

p-value: 0.271295% CI: [-10.8, 24.3]Chan and Zhang (1999) method

p-value: 0.002895% CI: [7.7, 47.5]Chan and Zhang (1999) method

p-value: 0.000395% CI: [14.7, 56.4]Chan and Zhang (1999) method

Secondary

Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only

The PASI quantified the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI was a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score could vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI =0.1Ah(Eh+Ih+Sh) + 0.2Au(Eu+Iu+Su) + 0.3At(Et+It+St) + 0.4Al(El+Il+Sl) (A= PASI area score,S=scaling)PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. 95% confidence interval was based on Blyth-Still-Casella method.

Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12

Population: ITT analysis set included all participants randomly assigned to study intervention. All participants reported under 'Number of Participants Analyzed' contributed data to the table; however, may not have evaluable data for every row. Here, 'Number Analyzed' signifies participants evaluable for the specified rows. For this OM, data collection was not planned for the 3 arms of AD Vehicle QD, AD PF-07038124 0.01% QD and AD PF-07038124 0.03% QD.

Arm	Measure	Group	Value (MEAN)	Dispersion
Atopic Dermatitis: Vehicle Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	-0.60 Units on a scale	Standard Deviation 1.796
Atopic Dermatitis: Vehicle Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	-3.93 Units on a scale	Standard Deviation 3.398
Atopic Dermatitis: Vehicle Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	-3.23 Units on a scale	Standard Deviation 3.584
Atopic Dermatitis: Vehicle Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	-1.53 Units on a scale	Standard Deviation 2.192
Atopic Dermatitis: Vehicle Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	-3.57 Units on a scale	Standard Deviation 3.946
Atopic Dermatitis: Vehicle Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	-1.70 Units on a scale	Standard Deviation 3.245
Atopic Dermatitis: Vehicle Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	-2.13 Units on a scale	Standard Deviation 3.451
Atopic Dermatitis: PF-07038124 0.01% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	-4.45 Units on a scale	Standard Deviation 3.486
Atopic Dermatitis: PF-07038124 0.01% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	-3.65 Units on a scale	Standard Deviation 2.639
Atopic Dermatitis: PF-07038124 0.01% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	-3.09 Units on a scale	Standard Deviation 2.332
Atopic Dermatitis: PF-07038124 0.01% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	-3.70 Units on a scale	Standard Deviation 3.059
Atopic Dermatitis: PF-07038124 0.01% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	-4.53 Units on a scale	Standard Deviation 3.556
Atopic Dermatitis: PF-07038124 0.01% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	-2.75 Units on a scale	Standard Deviation 2.315
Atopic Dermatitis: PF-07038124 0.01% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	-1.74 Units on a scale	Standard Deviation 1.529
Atopic Dermatitis: PF-07038124 0.03% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	-4.54 Units on a scale	Standard Deviation 3.143
Atopic Dermatitis: PF-07038124 0.03% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	-1.69 Units on a scale	Standard Deviation 2.053
Atopic Dermatitis: PF-07038124 0.03% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	-2.41 Units on a scale	Standard Deviation 2.496
Atopic Dermatitis: PF-07038124 0.03% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	-3.50 Units on a scale	Standard Deviation 2.861
Atopic Dermatitis: PF-07038124 0.03% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	-4.73 Units on a scale	Standard Deviation 3.383
Atopic Dermatitis: PF-07038124 0.03% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	-4.87 Units on a scale	Standard Deviation 3.369
Atopic Dermatitis: PF-07038124 0.03% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	-4.84 Units on a scale	Standard Deviation 3.53
Psoriasis: PF-07038124 0.06% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	-4.77 Units on a scale	Standard Deviation 3.694
Psoriasis: PF-07038124 0.06% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	-6.07 Units on a scale	Standard Deviation 4.058
Psoriasis: PF-07038124 0.06% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	-5.74 Units on a scale	Standard Deviation 3.973
Psoriasis: PF-07038124 0.06% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	-3.84 Units on a scale	Standard Deviation 3.357
Psoriasis: PF-07038124 0.06% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	-2.66 Units on a scale	Standard Deviation 2.064
Psoriasis: PF-07038124 0.06% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	-6.51 Units on a scale	Standard Deviation 4.002
Psoriasis: PF-07038124 0.06% Ointment	Change From Baseline in Psoriasis Area and Severity Index (PASI) Total Score at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	-5.39 Units on a scale	Standard Deviation 3.797

Secondary

Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis

The investigator or designee assessed tolerability at the site of study intervention application, immediately post-application of the study intervention. Skin Tolerability Grading System for non-lesional skin included grade 0 (No evidence of local intolerance), grade 1 (Mild-Minimal erythema and/or edema, slight glazed appearance), grade 2 (Moderate-Definite erythema and/or edema with peeling and/or cracking but needs no adaptation of posology), grade 3 (Severe-Erythema, edema glazing with fissures, few vesicles or papules: consider removing topical agent \[if still in place\], grade 4 (very severe- Strong reaction spreading beyond the treated area, bullous reaction, erosions: removal of topical agent \[if still in place\].

Time frame: From start of study treatment (Day 1) up to Week 12

Population: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention.

Arm	Measure	Category	Value (COUNT_OF_PARTICIPANTS)
Atopic Dermatitis: Vehicle Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Missing	0 Participants
Atopic Dermatitis: Vehicle Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 1 (Mild)	0 Participants
Atopic Dermatitis: Vehicle Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 3 (Severe)	0 Participants
Atopic Dermatitis: Vehicle Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 0 (None)	44 Participants
Atopic Dermatitis: Vehicle Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 2 (Moderate)	0 Participants
Atopic Dermatitis: Vehicle Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 4 (Very severe)	0 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 0 (None)	42 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 3 (Severe)	0 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Missing	0 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 1 (Mild)	0 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 4 (Very severe)	0 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 2 (Moderate)	0 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 4 (Very severe)	0 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 2 (Moderate)	0 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Missing	0 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 3 (Severe)	0 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 0 (None)	42 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 1 (Mild)	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 4 (Very severe)	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 0 (None)	32 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 1 (Mild)	1 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 2 (Moderate)	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 3 (Severe)	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Missing	1 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 3 (Severe)	0 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 1 (Mild)	1 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 4 (Very severe)	0 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Missing	0 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 2 (Moderate)	0 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 0 (None)	32 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 2 (Moderate)	0 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 3 (Severe)	0 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 1 (Mild)	1 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 4 (Very severe)	0 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 0 (None)	34 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Missing	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 2 (Moderate)	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 1 (Mild)	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Missing	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 3 (Severe)	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 4 (Very severe)	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants According to Worst Severity Grades in Local Skin Tolerability: Participants With Atopic Dermatitis and Plaque Psoriasis	Grade 0 (None)	33 Participants

Secondary

Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis

A standard 12-lead ECG utilizing limb leads was collected using ECG machine that automatically calculated the heart rate and measured pulse rate, QT, and QTc intervals and QRS complex. Clinically significant findings (including, but not limited to, changes from baseline in QTcF after enrollment) were determined by the investigator or qualified designee.

Time frame: From start of study treatment (Day 1) up to Week 12

Population: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Atopic Dermatitis: Vehicle Ointment	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants

Secondary

Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis

Temperature, pulse rate, and blood pressure were assessed in vital sign examination. Body temperature was collected using oral, tympanic, axillary or temporal methods. Blood pressure and pulse rate measurements were assessed with the participant in a supine or seated position using a completely automated device after at least 5 minutes of rest for the participant. Clinically significant changes were determined by the investigator.

Time frame: From start of study treatment (Day 1) up to Week 12

Population: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Atopic Dermatitis: Vehicle Ointment	Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Clinically Significant Changes in Vital Signs: Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants

Secondary

Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis

Laboratory assessments included hematology, clinical chemistry and urinalysis. Clinically significant abnormal laboratory findings were those which were not associated with the underlying disease, unless judged by the investigator to be more severe than expected for the participant's condition.

Time frame: From start of study treatment (Day 1) up to Week 12

Population: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Atopic Dermatitis: Vehicle Ointment	Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis	18 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis	27 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis	18 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis	14 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis	14 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis	13 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Laboratory Abnormalities: Participants With Atopic Dermatitis and Plaque Psoriasis	15 Participants

Secondary

Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis

An SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect, was a suspected transmission via a Pfizer product of an infectious agent, pathogenic or non-pathogenic or other important medical events.

Time frame: From start of study treatment up to 35 days after last dose of treatment (up to 19 weeks)

Population: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Atopic Dermatitis: Vehicle Ointment	Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis	1 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis	1 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis	0 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Serious Adverse Events (SAEs): Participants With Atopic Dermatitis and Plaque Psoriasis	1 Participants

Secondary

Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis

An AE was any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered TEAE if the event occurred on or after the first dosing date but before the last dose plus the lag time (35 days).

Time frame: From start of study treatment up to 35 days after last dose of treatment (up to 19 weeks)

Population: Safety analysis set included all participants randomly assigned to study intervention who received at least 1 dose of study intervention.

Arm	Measure	Value (COUNT_OF_PARTICIPANTS)
Atopic Dermatitis: Vehicle Ointment	Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis	20 Participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis	28 Participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis	19 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis	9 Participants
Psoriasis: PF-07038124 0.01% Ointment	Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis	13 Participants
Psoriasis: PF-07038124 0.03% Ointment	Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis	11 Participants
Psoriasis: PF-07038124 0.06% Ointment	Number of Participants With Treatment Emergent Adverse Events (AEs): Participants With Atopic Dermatitis and Plaque Psoriasis	19 Participants

Secondary

Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only

The PP-NRS was a daily participant reported assessment of intensity of pruritus on an 11-point numerical rating scale ranging from 0 ('No Itch) to 10 ('Worst Itch Imaginable'), with a 24-hour recall period. Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. For the PP-NRS score, baseline was defined as the average of all values recorded between Day -7 (7 days prior to dosing) and Day -1 (1 day prior to dosing). In this OM, percentages of plaque psoriasis participants (18-75 years old) with \>=4 points of reduction in weekly averages of PP-NRS from baseline are reported (percentage based on number of participants with baseline \>=4).

Time frame: Week 1, 2, 4, 6, 8, 10 and 12

Population: ITT analysis set included all participants randomly assigned to study intervention.Here,'Overall Number of Participants Analyzed'=participants evaluable for this OM,all participants reported under'Overall Number of Participants Analyzed'contributed data to table but may not have evaluable data for every row.Here,'Number Analyzed'=participants evaluable for specified rows.For this OM,data collection was not planned for 3 arms:AD Vehicle QD, PF-07038124 0.01% QD,AD PF-07038124 0.03% QD ointment.

Arm	Measure	Group	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	17.4 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	17.4 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	8.7 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	4.3 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	4.3 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	17.4 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	4.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	40.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	40.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	13.6 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	31.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	22.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	36.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	33.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	12.5 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	20.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	25.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	25.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	25.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	29.2 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	42.1 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	26.3 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	47.4 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	47.4 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	21.1 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	5.3 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Adult (18-75 Years Old) Participants With >=4 Points of Reduction From Baseline in Weekly Average of PP-NRS at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	52.6 Percentage of participants

Comparison: Week 1p-value: 0.727895% CI: [-21.9, 11.5]Chan and Zhang (1999) method

Comparison: Week 1p-value: 0.254895% CI: [-11.5, 28.2]Chan and Zhang (1999) method

Comparison: Week 1p-value: 0.516295% CI: [-17.5, 21.9]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.166395% CI: [-11.4, 30.7]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.060595% CI: [-4.2, 38.3]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.059295% CI: [-5.4, 41.6]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.124695% CI: [-8.6, 37.4]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.078995% CI: [-7.3, 39.7]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.088995% CI: [-6.4, 43.7]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.009795% CI: [4.2, 50.7]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.029495% CI: [-0.8, 43.6]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.001895% CI: [10.9, 62.2]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.049595% CI: [-3.8, 48.9]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.28995% CI: [-17.3, 32.4]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.010395% CI: [5.1, 62]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.108895% CI: [-7.8, 44.8]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.271995% CI: [-14, 36.2]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.022795% CI: [0.4, 56.6]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.049595% CI: [-3.8, 48.9]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.124695% CI: [-10.6, 40.6]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.022795% CI: [0.4, 56.6]Chan and Zhang (1999) method

Secondary

Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only

The PP-NRS was a daily participant reported assessment of intensity of pruritus on an 11-point numerical rating scale ranging from 0 ('No Itch) to 10 ('Worst Itch Imaginable'), with a 24-hour recall period. Participants were asked to assess their itch intensity over the past 24 hours, on a scale from 0 (no itching) to 10 (worst possible itching). Higher scores indicated worse itch. For the PP-NRS score, baseline was defined as the average of all values recorded between Day -7 (7 days prior to dosing) and Day -1 (1 day prior to dosing). In this OM, percentages of AD participants with \>=4 points of reduction in weekly averages of PP-NRS from baseline are reported (percentage based on number of participants with baseline \>=4).

Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12

Population: ITT analysis set included all participants randomly assigned to study intervention. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure. For this outcome measure (OM), data collection was not planned for the 4 arms of Psoriasis Vehicle QD, Psoriasis PF-07038124 0.01% QD, Psoriasis PF-07038124 0.03% and Psoriasis PF-07038124 0.06% ointment.

Arm	Measure	Group	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 4	10.0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 12	15.0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 8	17.5 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 6	17.5 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 2	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 1	2.5 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 10	17.5 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 8	21.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 1	5.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 2	18.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 4	23.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 6	21.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 10	23.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 12	26.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 8	29.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 2	14.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 12	35.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 10	26.5 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 1	0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 6	26.5 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 4 Points of Reduction From Baseline in Weekly Average of Peak Pruritus Numerical Rating Scale (PP-NRS) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 4	29.4 Percentage of participants

Comparison: Week 1p-value: 0.325595% CI: [-8.5, 15.8]Chan and Zhang (1999) method

Comparison: Week 1p-value: 0.718195% CI: [-13.3, 8.3]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.002295% CI: [7, 34.3]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.006495% CI: [3.7, 31.1]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.065995% CI: [-3.4, 31.5]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.018995% CI: [0.9, 38.5]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.396295% CI: [-14.9, 22.3]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.233395% CI: [-10.4, 29.1]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.396295% CI: [-14.9, 22.3]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.135395% CI: [-7.9, 32.7]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.279195% CI: [-12.8, 25.7]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.233395% CI: [-10.4, 29.1]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.129595% CI: [-7.3, 30.6]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.024795% CI: [0.1, 40.2]Chan and Zhang (1999) method

Secondary

Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only

EASI quantified severity of AD based on severity of lesion clinical signs and % of body surface area(BSA)affected.Severity of clinical signs of AD lesions (erythema \[E\], induration/papulation\[I\],excoriation\[Ex\] and lichenification\[L\]) were scored separately for each of 4 body regions(head and neck, upper limbs, trunk \[including axillae and groin)\], lower limbs \[including buttocks\]) on a 4-point scale:0= absent; 1= mild;2= moderate;3= severe.EASI area score was based on % BSA with AD in body region: 0(0%), 1(\>0 to \<10%),2 (10 to \<30%), 3(30 to \<50%), 4(50 to \<70%), 5(70 to \<90%) and 6(90 to 100%).Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu)+0.3\*At\*(Et+It+Ext+Lt)+0.4\*Al\*(El+Il+Exl+Ll);A= EASI area score;h= head and neck;u= upper limbs;t= trunk;l= lower limbs.Total EASI score=0.0 to 72.0, higher scores indicate greater severity of AD.EASI 75 response was defined as at least a 75% reduction in EASI relative to Baseline.95% CI was based on Blyth-Still-Casella method.

Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12

Population: ITT analysis set included all participants randomly assigned to study intervention. For this OM, data collection was not planned for the 4 arms of Psoriasis Vehicle QD, Psoriasis PF-07038124 0.01% QD, Psoriasis PF-07038124 0.03% and Psoriasis PF-07038124 0.06% ointment.

Arm	Measure	Group	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 2	2.3 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 8	15.9 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 6	13.6 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 1	2.3 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 12	13.6 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 10	13.6 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 4	11.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 6	21.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 1	2.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 2	11.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 4	11.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 8	19.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 10	21.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 12	26.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 8	14.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 2	7.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 12	28.6 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 10	19.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 6	16.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 4	16.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >= 75% Improvement in Eczema Area and Severity Index Total Score (EASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Atopic Dermatitis Only	Week 1	4.8 Percentage of participants

Comparison: Week 1p-value: 0.570195% CI: [-10.2, 10.7]Chan and Zhang (1999) method

Comparison: Week 1p-value: 0.326995% CI: [-8.4, 14.1]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.053295% CI: [-2, 23.7]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.170595% CI: [-6.1, 17.6]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.512395% CI: [-14.4, 15.7]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.275195% CI: [-10.7, 22.1]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.273695% CI: [-8.9, 24.8]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.396795% CI: [-13, 19.8]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.399795% CI: [-13.6, 20.2]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.546195% CI: [-17.7, 15.3]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.273695% CI: [-8.9, 24.8]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.275495% CI: [-11, 22.1]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.097795% CI: [-4.8, 30.3]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.054295% CI: [-2.8, 33.2]Chan and Zhang (1999) method

Secondary

Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only

The PASI quantified the severity of a participant's psoriasis based on both, lesion severity and the percent of BSA affected. PASI was a composite scoring by the investigator of degree of erythema, induration, and scaling (each scored separately) for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin\], and lower limbs \[including buttocks\]), with adjustment for the percent of BSA involved for each body region and for the proportion of the body region to the whole body. The PASI score could vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representing greater severity of psoriasis. PASI score =0.1Ah(Eh+Ih+Sh) + 0.2Au(Eu+Iu+Su) + 0.3At(Et+It+St) + 0.4Al(El+Il+Sl) (A= PASI area score,S=scaling)PASI 75 response was defined as at least a 75 percent (%) reduction in PASI relative to Baseline. 95% confidence interval was based on Blyth-Still-Casella method.

Time frame: Baseline, Week 1, 2, 4, 6, 8, 10 and 12

Arm	Measure	Group	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 1	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 10	8.8 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 8	2.9 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 2	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 12	14.7 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 4	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 6	0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 10	30.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 6	21.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 4	15.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 8	18.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 12	27.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 2	9.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 1	3.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 6	22.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 1	0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 2	2.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 4	14.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 8	25.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 10	28.6 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 12	25.7 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 4	21.2 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 12	51.5 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 10	48.5 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 2	15.2 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 1	9.1 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 8	33.3 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With >=75% Improvement in Psoriasis Area and Severity Index Total Score (PASI-75) From Baseline, at Week 1, 2, 4, 6, 8, 10, 12: Participants With Plaque Psoriasis Only	Week 6	33.3 Percentage of participants

Comparison: Week 4p-value: 0.010495% CI: [3.2, 32]Chan and Zhang (1999) method

Comparison: Week 1p-value: 0.257895% CI: [-7.8, 15.8]Chan and Zhang (1999) method

Comparison: Week 1p-value: 195% CI: [-10.6, 10.1]Chan and Zhang (1999) method

Comparison: Week 1p-value: 0.043695% CI: [-2.1, 24.3]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.043695% CI: [-2.1, 24.3]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.269795% CI: [-7.8, 14.9]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.010495% CI: [3.2, 32]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.012995% CI: [2.6, 30.3]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.002495% CI: [8, 38.9]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.002495% CI: [8, 38.9]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.001895% CI: [9.5, 40.1]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.000195% CI: [17.8, 51.8]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.025995% CI: [-0.1, 32.5]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.003895% CI: [6.3, 40.4]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.000795% CI: [12.2, 48.9]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.014695% CI: [2.1, 41.2]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.020595% CI: [1, 38.9]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.000295% CI: [17.1, 59.3]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.124595% CI: [-7.8, 32.6]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.143195% CI: [-9.1, 31.5]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.000795% CI: [12.2, 56.8]Chan and Zhang (1999) method

Secondary

Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only

IGA assessed severity of AD on 5-point scale ranging from 0(clear)to 4(severe)higher scores indicate more severity,reflecting a global consideration of erythema (ery),induration and scaling. Clinical evaluator assessed overall severity of AD and assigned IGA score as follows: 0 (clear) no inflammatory signs of AD; 1=almost clear, AD not fully cleared-light pink residual lesions(except post-inflammatory hyperpigmentation),just perceptible ery, papulation/induration lichenification, excoriation, no oozing/crusting; 2=mild AD with light red lesions, slight but definite ery, papulation/induration, lichenification, excoriation, no oozing/crusting; 3=moderate AD with red lesions, moderate ery, papulation/induration, lichenification, excoriation, slight oozing/crusting; 4=severe AD with deep dark red lesions, severe ery, papulation/induration, lichenification, excoriation, moderate to severe oozing/crusting.95%confidence interval was based on Blyth-Still-Casella method.

Time frame: Baseline, Week 1, 2, 4, 6, 8, and 10

Population: ITT analysis set included all participants randomly assigned to study intervention. For this outcome measure (OM), data collection was not planned for the 4 arms of Psoriasis Vehicle QD, Psoriasis PF-07038124 0.01% QD, Psoriasis PF-07038124 0.03% and Psoriasis PF-07038124 0.06% ointment.

Arm	Measure	Group	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 1	2.3 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 2	2.3 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 4	9.1 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 6	6.8 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 8	6.8 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 10	11.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 10	19.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 1	4.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 6	14.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 8	16.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 2	7.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 4	14.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 2	9.5 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 4	11.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 10	14.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 6	14.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 1	4.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >= 2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Atopic Dermatitis Only	Week 8	9.5 Percentage of participants

Comparison: Week 1p-value: 0.326995% CI: [-8.4, 14.1]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.170595% CI: [-6.1, 17.6]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.111895% CI: [-3.9, 20.5]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.275195% CI: [-9.5, 20.5]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.385795% CI: [-11.4, 17.6]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.142995% CI: [-6.4, 22.6]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.111995% CI: [-4.4, 25.3]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.375595% CI: [-10.7, 16.7]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.254795% CI: [-8.4, 24.3]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.392895% CI: [-12.7, 18.6]Chan and Zhang (1999) method

Secondary

Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only

IGA assessed severity of AD on 5-point scale ranging from 0(clear)to 4(severe)higher scores indicate more severity,reflecting a global consideration of erythema (ery),induration and scaling. Clinical evaluator assessed overall severity of AD and assigned IGA score as follows: 0 (clear) no inflammatory signs of AD; 1=almost clear, AD not fully cleared-light pink residual lesions(except post-inflammatory hyperpigmentation),just perceptible ery, papulation/induration lichenification, excoriation, no oozing/crusting; 2=mild AD with light red lesions, slight but definite ery, papulation/induration, lichenification, excoriation, no oozing/crusting; 3=moderate AD with red lesions, moderate ery, papulation/induration, lichenification, excoriation, slight oozing/crusting; 4=severe AD with deep dark red lesions, severe ery, papulation/induration, lichenification, excoriation, moderate to severe oozing/crusting. 95% confidence interval was based on Blyth-Still-Casella method.

Time frame: Week 1, 2, 4, 6, 8, 10 and 12

Arm	Measure	Group	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 2	4.5 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 8	11.4 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 12	15.9 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 4	11.4 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 10	15.9 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 1	2.3 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 6	9.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 1	4.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 10	19.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 6	14.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 12	23.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 2	7.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 4	16.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 8	16.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 12	28.6 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 2	11.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 4	19.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 6	21.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 8	16.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 1	4.8 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With IGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Atopic Dermatitis Only	Week 10	19.0 Percentage of participants

Comparison: Week 1p-value: 0.326995% CI: [-8.4, 14.1]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.358595% CI: [-9.2, 15.5]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.12995% CI: [-5.3, 22.1]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.275195% CI: [-10.7, 22.1]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.254795% CI: [-8.4, 24.3]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.275195% CI: [-9.5, 20.5]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.065895% CI: [-3.8, 28.8]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.275195% CI: [-10.7, 22.1]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.399795% CI: [-13.6, 20.2]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.273695% CI: [-9.5, 25.7]Chan and Zhang (1999) method

Comparison: Week 12p-value: 0.111995% CI: [-5.6, 31]Chan and Zhang (1999) method

Secondary

Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only

Time frame: Baseline, Week 1, 2, 4, 6, 8, and 10

Arm	Measure	Group	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 1	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 2	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 4	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 6	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 8	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 10	5.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 10	15.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 6	15.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 1	0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 4	6.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 2	6.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 8	9.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 2	5.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 4	17.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 6	17.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 10	31.4 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 8	28.6 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 1	0 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 8	27.3 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 10	39.4 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 2	9.1 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 6	24.2 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 1	3.0 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) and a Reduction From Baseline of >=2 Points at Weeks 1, 2, 4, 6, 8 and 10: Participants With Plaque Psoriasis Only	Week 4	15.2 Percentage of participants

Comparison: Week 1p-value: 195% CI: [-10.6, 11]Chan and Zhang (1999) method

Comparison: Week 1p-value: 195% CI: [-10.6, 10.1]Chan and Zhang (1999) method

Comparison: Week 1p-value: 0.257895% CI: [-7.8, 15.8]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.099395% CI: [-4.9, 20.7]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.11495% CI: [-5.3, 19.2]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.043695% CI: [-2.1, 24.3]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.099395% CI: [-4.9, 20.7]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.007195% CI: [4.9, 33.9]Chan and Zhang (1999) method

Comparison: Week 4p-value: 0.010495% CI: [3.2, 32]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.010495% CI: [3.2, 32]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.007195% CI: [4.9, 33.9]Chan and Zhang (1999) method

Comparison: Week 6p-value: 0.001195% CI: [10.4, 42.3]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.043695% CI: [-2.1, 24.3]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.000395% CI: [14.2, 46.3]Chan and Zhang (1999) method

Comparison: Week 8p-value: 0.000795% CI: [12.9, 45.8]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.125695% CI: [-6.6, 26.4]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.003895% CI: [7, 44.8]Chan and Zhang (1999) method

Comparison: Week 10p-value: 0.000795% CI: [12.8, 52.6]Chan and Zhang (1999) method

Secondary

Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only

The PGA of psoriasis was scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. Average erythema, induration, and scaling were scored separately over the whole body according to a 5-point severity scale (0 \[no symptom\] to 4 \[severe symptom\]). The total score was calculated as average of the 3 severity scores and rounded to the nearest whole number score to determine the PGA score and category (0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe). PGA response was defined as 0 (clear) or 1 (almost clear). 95% confidence interval was based on Blyth-Still-Casella method.

Time frame: Week 1, 2, 4, 6, 8, 10 and 12

Arm	Measure	Group	Value (NUMBER)
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	0 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	11.8 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	8.8 Percentage of participants
Atopic Dermatitis: Vehicle Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	9.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	15.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	15.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	6.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	6.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.01% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	15.2 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	17.1 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	34.3 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	2.9 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	40.0 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	28.6 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	5.7 Percentage of participants
Atopic Dermatitis: PF-07038124 0.03% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	17.1 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 2	9.1 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 4	15.2 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 6	24.2 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 12	45.5 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 8	27.3 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 10	39.4 Percentage of participants
Psoriasis: PF-07038124 0.06% Ointment	Percentage of Participants With PGA Score of Clear (0) or Almost Clear (1) at Weeks 1, 2, 4, 6, 8, 10 and 12: Participants With Plaque Psoriasis Only	Week 1	3.0 Percentage of participants

Comparison: Week 4p-value: 0.099395% CI: [-4.9, 20.7]Chan and Zhang (1999) method

Comparison: Week 2p-value: 0.043695% CI: [-2.1, 24.3]Chan and Zhang (1999) method

Comparison: Week 1p-value: 195% CI: [-10.6, 11]Chan and Zhang (1999) method

Comparison: Week 1p-value: 0.269795% CI: [-7.8, 14.9]Chan and Zhang (1999) method